Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In-Line Diagnostics, Inc.

This article was originally published in The Gray Sheet

Executive Summary

Raises $20 mil. in private equity financing. The Salt Lake City firm makes Crit-Line monitors to non-invasively measure hematocrit, oxygen saturation and changes in blood volume. The funds "will allow the company to expand its renal care operations and accelerate development of its other proprietary non-invasive technologies across a variety of medical specialties and applications," states Chairman Robert Steuer. The firm simultaneously announces Aug. 11 FDA 510(k) clearance of its Crit-Scan transcutaneous hematocrit monitoring device. The Crit-Scan is "the first non-invasive device used to measure whole blood hematocrit," the firm claims, and "virtually eliminates the need for finger sticks associated with blood tests and blood donation"

You may also be interested in...

Novartis Targets Ten Indications For Cosentyx

The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.

Zydus Cadila Strides Ahead With NASH Filing In India

Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.


Interview: Double Delight For ImmuPharma's Dimitriou

It has been a long and sometimes tortuous development path for Lupuzor but ImmuPharma's chief executive tells Scrip the company's faith in the lupus drug is bearing fruit.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts